Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9

References

• Abel S. M., Back D. J. Cortisol metabolism in vitro. III. Inhibition of microsomal 6β-hydroxylase and cytosolic 4-ene-reductase. Journal of Steroid Biochemistry and Molecular Biology 1993; 46: 827–832
   PubMed Web of Science ®Google Scholar
• Back D. J., Park B. K., Tjia J. F., Newby S. N. Sulphaphenazole and drug oxidation in man. British Journal of Clinical Pharmacology 1983; 16: 460–461
   PubMedGoogle Scholar
• Back D. J., Stevenson P., Tjia J. F. Comparative effects of two antimycotic agents ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cycloporine and ethoxycoumarin by human liver microsomes in vitro. British Journal of Clinical Pharmacology 1989; 28: 166–170
   PubMed Web of Science ®Google Scholar
• Back D. J., Tjia J. F., Abel S. M. Azoles, allylamines and drug metabolism. British Journal of Dermatology 1992; 126: 14–18
   PubMed Web of Science ®Google Scholar
• Back D. J., Tjia J. F., Karbwang J., Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology 1988; 26: 23–29
   PubMed Web of Science ®Google Scholar
• Berthou F., Flinois J.-P., Ratanasavanh D., Beaune P., Riche C., Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the steps of caffeine metabolism by human liver microsomes. Drug Metabolism and Disposition 1991; 19: 561–567
   PubMed Web of Science ®Google Scholar
• Brian W. R., Srivastava P. K., Umbenhauer D. R., Lloyd R. S., Guengerich F. P. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in. Saccharomyces cerevisiae. Biochemistry 1989; 28: 4993–4999
   Google Scholar
• Brown M. W., Meredith C. G., Maldonado A. L., Speeg K. V. Ketoconazole inhibition of oxidative drug metabolism: effect of age and gender. Clinical Research 1983; 31: 883–891
   Google Scholar
• Burke M. D., Thompson S., Elcombe C. R., Halpert J., Haaparanta T., Mayer R. T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochemical Pharmacology 1985; 34: 3337–3345
   PubMed Web of Science ®Google Scholar
• Cambell M. E., Grant D. M., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition 1987; 15: 237–249
   PubMedGoogle Scholar
• Christensen L. K., Hansen J. M., Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetes. Lancet 1963; ii: 1298–1301
   Google Scholar
• Clarke S. E., Ayrton A. D., Chenery R. J. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 1994; 24: 517–526
   PubMed Web of Science ®Google Scholar
• Clarke S. E., Baldwin S. J., Bloomer J. C., Ayrton A. D., Sozio R. S., Chenery R. J. Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chemical Research in Toxicology 1994a; 7: 836–842
   PubMed Web of Science ®Google Scholar
• Combalbert J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J. P., Maurel P. Metabolism of cyclosporin A. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily. Drug Metabolism and Disposition 1989; 17: 197–207
   PubMed Web of Science ®Google Scholar
• Daneshmend T. K., Warnock D. W. Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics 1988; 14: 13–34
   PubMed Web of Science ®Google Scholar
• Deluca J. G., Dysart G. R., Ranick D., Bradley M. O. A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog. Biochemical Pharmacology 1988; 37: 1731–1739
   PubMed Web of Science ®Google Scholar
• Dirvn H. A. A. M., Peters J. G. P., Gibson G. G., Peters W. H. M., Jongeneelen F. J. Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes. Biochemical Pharmacology 1991; 42: 1841–1844
   PubMedGoogle Scholar
• Doecke C. J., Veronese M. E., Pond S. M., Miners J. O., Birkett D. J., Sansom L. N., McManus M. E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. British Journal of Clinical Pharmacology 1991; 31: 125–130
   PubMed Web of Science ®Google Scholar
• Fabre G., Julian B., Saint-Aubert B., Joyeux H., Berger Y. Evidence of CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metabolism and Disposition 1993; 21: 978–985
   PubMed Web of Science ®Google Scholar
• Ferguson R. M., Sutherland D. E. R., Simmons R. L., Najarian J. S. Ketoconazole, cyclosporin metabolism and renal transplantation. Lancet 1982; ii: 882–883
   Google Scholar
• First M. R., Schroeder T. J., Michael A., Hariharan S., Weiskittel P., Alexander J. W. Cyclosporine-ketoconazole interaction. Transplantation 1993; 55: 1000–1004
   PubMed Web of Science ®Google Scholar
• Funae Y., Imaoka S. Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats. Biochimica et Biophysica Acta 1987; 926: 349–358
   PubMed Web of Science ®Google Scholar
• Gascon M. P., Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. European Journal of Clinical Pharmacology 1991; 41: 573–578
   PubMed Web of Science ®Google Scholar
• Gluckman E., Devergie A., Lokiec F., Poirier O., Baumelou A. Nephrotoxicity of cyclosporin A in bone-marrow transplantation. Lancet 1981; ii: 144–145
   Google Scholar
• Glynn A. M., Slaughter R. L., Brass C. D., D'Ambrosio R., Jusko W. J. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clinical Pharmacology and Therapeutics 1986; 39: 654–659
   PubMed Web of Science ®Google Scholar
• Graybill J. R., Drutz D. J. Ketoconazole: a major innovation for treatment of fungal disease. Archives of International Medicine 1980; 93: 921–923
   Google Scholar
• Guengerich F. P. Mechanism-based inactivation of human liver microsomal cytochrome P450 IIIA4 by gestodene. Chemical Research in Toxicology 1990; 3: 363–371
   PubMed Web of Science ®Google Scholar
• Harrell A. W., Wheeler S. M., Pennick M., Clarke S. E., Chenery R. J. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6β-hydroxylation of testosterone in human liver microsomes. Drug Metabolism and Disposition 1993; 21: 18–23
   PubMedGoogle Scholar
• Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speight T. M., Avery G. S. Ketoconazole: a review of its therapeutic efficacy in superficial and systematic fungal infections. Drugs 1982; 23: 1–36
   PubMed Web of Science ®Google Scholar
• Leatherbarrow R. J. Granfit Version 3.0. Erithacus Software Ltd., StainesUK 1992
   Google Scholar
• Maurice M., Emiliani S., Dalet-Beluche I., Derancourt J., Lange R. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. European Journal of Biochemistry 1991; 200: 511–517
   PubMedGoogle Scholar
• Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture. FASEB Journal 1992; 6: 752–758
   PubMed Web of Science ®Google Scholar
• McInnes G. T., Brodie M. J. Drug interactions that matter. A critical reappraisal. Drugs 1988; 36: 83–110
   PubMed Web of Science ®Google Scholar
• Meier U. T., Kronbach T., Meyer U. A. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Analytical Biochemistry 1985; 151: 286–291
   PubMed Web of Science ®Google Scholar
• Meredith C. G., Maldonado A. L., Speeg J. R. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metabolism and Disposition 1985; 13: 156–162
   PubMed Web of Science ®Google Scholar
• Miners J. O., Smith K. J., Robson R. A., McManus M. E., Veronese M. E., Birkett D. J. Tolbutamide hydroxylation by human liver microsomes, kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology 1988; 37: 1137–1144
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Tetsuya K., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: update on the new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biology 1993; 12: 1–51
   PubMed Web of Science ®Google Scholar
• Otton S. V., Crewe H. K., Lennard M. S., Tucker G. T., Woods H. F. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1988; 247: 242–247
   PubMed Web of Science ®Google Scholar
• Peter R., Böcker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. 1990
   Google Scholar
• Chemical Research in Toxicology, 3: 566–573
   PubMedGoogle Scholar
• Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., Maurel P. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 1990; 18: 595–606
   PubMed Web of Science ®Google Scholar
• Pond S. M., Birkett D. J., Wade D. N. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenylbutazone, sulfaphenazole. Clinical Pharmacology and Therapeutics 1977; 22: 573–579
   PubMed Web of Science ®Google Scholar
• Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R., Stevens D. A. Ketoconazole blocks testosterone synthesis. Archives of International Medicine 1982; 142: 2137–2140
   PubMed Web of Science ®Google Scholar
• Relling M. V., Aoyama T., Gonzalez F. J., Meyer U. A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. Journal of Pharmacology and Experimental Therapeutics 1990; 252: 442–447
   PubMed Web of Science ®Google Scholar
• Robson R. A., Miners J. O., Matthews A. P., Stupans D. M., McManus M. E., Birkett D. J. Characterization of theophylline metabolism by human liver microsomes. Biochemical Pharmacology 1988; 37: 1651–1659
   PubMed Web of Science ®Google Scholar
• Rowland M., Matin S. B., Thiessen J., Karam J. Kinetics of tolbutamide interactions. Drug Interactions, P. L. Morselli, S. N. Cohen, S. Giorattini. Raven, New York 1974; 199–210
   Google Scholar
• Sheets J. J., Mason J. I. Ketoconazole: A potent inhibitor of cytochrome P450-dependent drug metabolism in rat liver. Drug Metabolism and Disposition 1984; 12: 603–606
   PubMed Web of Science ®Google Scholar
• Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk C. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985; 150: 76–85
   PubMed Web of Science ®Google Scholar
• Sonino N. The use of ketoconazole as an inhibitor of steroid production. New England Journal of Medicine 1987; 317: 812–818
   PubMed Web of Science ®Google Scholar
• Speeg K. V., Meredith C. G., Maldonado A. L. Ketoconazole inhibits hepatic oxidative drug metabolism. Hepatology 1983; 3: 860–861
   Google Scholar
• Speirs C. J., Murray S., Boobis A. R., Seddon C. E., Davies D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. British Journal of Clinical Pharmacology 1986; 22: 739–743
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Miners J. O., Randles D., Gregov D., Birkett D. J. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clinical Pharmacology and Therapeutics 1990; 47: 403–411
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Doecke C. J., Mackenzie P. I., McManus M. E., Miners J. O., Rees D. L. P., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal 1993; 289: 533–538
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450. Archives of Biochemistry and Biophysics 1991; 290: 160–166
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C., Becker G. W., Vandenbranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archives of Biochemistry and Biophysics 1993; 306: 240–245
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322–1329
   PubMed Web of Science ®Google Scholar
• Zanger U. M., Vilbois F., Hardwich J., Meyer U. A. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447–5454
   PubMed Web of Science ®Google Scholar
• Zhou-Pan X.-R., Seree E., Zhou X.-J., Placidi M., Maurel P., Barra Y., Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Research 1993; 53: 5121–5126
   PubMed Web of Science ®Google Scholar